Shende A, Chikhalkar S
Indian J Dermatol. 2024; 69(2):145-151.
PMID: 38841213
PMC: 11149824.
DOI: 10.4103/ijd.ijd_1071_23.
Marghalani S, Alghamdi Y, Albrakati B, Huwait H, Mohanna A
Cureus. 2024; 16(3):e56310.
PMID: 38628985
PMC: 11019476.
DOI: 10.7759/cureus.56310.
Duzett L, Mercado G, Tasouli-Drakou V, Kane A, Tam A
Dermatol Reports. 2024; 16(1):9742.
PMID: 38623364
PMC: 11017724.
DOI: 10.4081/dr.2023.9742.
Potestio L, Martora F, Cacciapuoti S, Megna M, Villani A, Ruggiero A
Clin Cosmet Investig Dermatol. 2024; 17:51-57.
PMID: 38222859
PMC: 10785683.
DOI: 10.2147/CCID.S447834.
Bin Rubaian N, Aljalfan A, Almuhaidib S
J Family Community Med. 2023; 30(3):161-170.
PMID: 37675215
PMC: 10479027.
DOI: 10.4103/jfcm.jfcm_3_23.
A Review of Pityriasis Rosea in Relation to SARS-CoV-2/COVID-19 Infection and Vaccination.
Wong N, Cascardo C, Mansour M, Qian V, Potts G
Cureus. 2023; 15(5):e38772.
PMID: 37303403
PMC: 10250113.
DOI: 10.7759/cureus.38772.
Cutaneous Adverse Drug Reactions (CADRs) to COVID19 Vaccines: A Case Series.
Purushottam M, Rangappa V, Betkerur J, Kombettu A, Shastry V
Indian Dermatol Online J. 2023; 14(3):383-387.
PMID: 37266107
PMC: 10231698.
DOI: 10.4103/idoj.idoj_109_22.
Manifestation of pityriasis rosea and pityriasis rosea-like eruptions after Covid-19 vaccine: A systematic review.
Khan I, Elsanousi A, Shareef A, Tebha S, Arif A, Gul S
Immun Inflamm Dis. 2023; 11(4):e804.
PMID: 37102660
PMC: 10091373.
DOI: 10.1002/iid3.804.
Pityriasis rosea and pityriasis rosea-like eruption after anti-SARS-CoV-2 vaccination: a report of five cases and review of the literature.
Veraldi S, Boneschi V, Cusini M, Maronese C
Dermatol Reports. 2023; 15(1):9503.
PMID: 37063394
PMC: 10099291.
DOI: 10.4081/dr.2022.9503.
Vesiculobullous and Other Cutaneous Manifestations of COVID-19 Vaccines: a Scoping and Narrative Review.
Mahmood F, Cyr J, Li A, Lipson J, Pratt M, Beecker J
J Cutan Med Surg. 2023; 27(3):260-270.
PMID: 36789514
PMC: 10291118.
DOI: 10.1177/12034754231156561.
Global prevalence and clinical manifestations of cutaneous adverse reactions following COVID-19 vaccination: A systematic review and meta-analysis.
Washrawirul C, Triwatcharikorn J, Phannajit J, Ullman M, Susantitaphong P, Rerknimitr P
J Eur Acad Dermatol Venereol. 2022; 36(11):1947-1968.
PMID: 35666609
PMC: 9348179.
DOI: 10.1111/jdv.18294.
Morbilliform Eruption After Administration of Second Dose of Oxford/AstraZeneca Vaccine.
Alhammad N, Milibary H, Baghdadi R, Alawadi T, Hudairy R
Cureus. 2022; 14(5):e24649.
PMID: 35663693
PMC: 9156371.
DOI: 10.7759/cureus.24649.
COVID-19 at a Glance: An Up-to-Date Overview on Variants, Drug Design and Therapies.
Iacopetta D, Ceramella J, Catalano A, Saturnino C, Pellegrino M, Mariconda A
Viruses. 2022; 14(3).
PMID: 35336980
PMC: 8950852.
DOI: 10.3390/v14030573.
Covid-19 vaccine associated erythema nodosum: Factors to consider.
Damevska K, Simeonovski V
Dermatol Ther. 2022; 35(5):e15410.
PMID: 35218272
PMC: 9111800.
DOI: 10.1111/dth.15410.
Potential risk factors for Varicella-zoster virus reactivation after COVID-19 vaccination.
May Lee M, Macchi S, Mora E, Feliciani C
J Cosmet Dermatol. 2022; 21(4):1347-1349.
PMID: 35184368
PMC: 9115251.
DOI: 10.1111/jocd.14871.
SARS-CoV-2 vaccine-related cutaneous manifestations: a systematic review.
Avallone G, Quaglino P, Cavallo F, Roccuzzo G, Ribero S, Zalaudek I
Int J Dermatol. 2022; 61(10):1187-1204.
PMID: 35141881
PMC: 9111829.
DOI: 10.1111/ijd.16063.
First Case of Erythema Nodosum Associated With Pfizer Vaccine.
Aly M, ALShehri A, Mohammed A, Almalki A, Ahmed W, Almuflihi A
Cureus. 2021; 13(11):e19529.
PMID: 34934549
PMC: 8668049.
DOI: 10.7759/cureus.19529.
